TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.78% | -73.01% | -82.97% | -91.68% | 132.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.78% | -73.01% | -82.97% | -91.68% | 132.99% |
| Cost of Revenue | -16.35% | 15.48% | 26.62% | 14.13% | -502.92% |
| Gross Profit | 5.33% | -33.73% | -45.70% | -62.20% | 660.25% |
| SG&A Expenses | 30.20% | 25.70% | 19.02% | -8.82% | 0.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.84% | 17.59% | 24.83% | 8.10% | 31.38% |
| Operating Income | -71.90% | -31.82% | -38.62% | -37.95% | -14.52% |
| Income Before Tax | -82.58% | -29.96% | -31.67% | -33.59% | -4.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.58% | -29.96% | -31.67% | -33.59% | -4.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.58% | -29.96% | -31.67% | -33.59% | -4.75% |
| EBIT | -71.90% | -31.82% | -38.62% | -37.95% | -14.52% |
| EBITDA | -79.31% | -34.66% | -41.54% | -41.78% | -16.96% |
| EPS Basic | -54.30% | -16.49% | -17.44% | 32.45% | 47.26% |
| Normalized Basic EPS | -49.59% | -16.51% | -17.44% | 32.43% | 47.26% |
| EPS Diluted | -54.30% | -16.49% | -17.44% | 32.45% | 47.26% |
| Normalized Diluted EPS | -49.59% | -16.51% | -17.44% | 32.43% | 47.26% |
| Average Basic Shares Outstanding | 18.32% | 11.57% | 12.12% | 97.74% | 98.64% |
| Average Diluted Shares Outstanding | 18.32% | 11.57% | 12.12% | 97.74% | 98.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |